



The Next Wave:

Navigating Emerging Mass Torts and the Data Behind the Docket

May 28, 2026

Sponsored by:

Alan Gray
A PREMIA COMPANY

MEET YOUR PANEL



John Delascio, Esq.

Partner

Hinshaw & Culbertson LLP

E-Mail: jdelascio@hinshawlaw.com

Telephone: 312-704-3664



Leslie Lombardy, Esq.

Partner

O'Toole Scrivo, LLC

E-Mail: llombardy@oslaw.com

Telephone: 973-559-9834



Barry Trilla

Director for Quantitative Services

Alan Gray

E-Mail: btrilla@alangray.com

Telephone: 708-250-4113



Stacey White

AVP, Direct Claims

Resolute Management, Inc.

E-Mail: swhite@resolutemgmt.com

Telephone: (312) 345-2496

TODAY'S AGENDA



**Silica
Litigation**

**Hair Relaxer
Litigation**

**PFA's
Litigation**


**GLP1/
Ozempic
Litigation**

**Roundup
Litigation**

**Depo-Provera
Litigation**

Q&A

MAP: Silica Litigation



As of May 2026, there is no multidistrict litigation (“MDL”) for silica cases.

Likewise, there is no silica-specific mass tort designation or multicounty litigation (“MCL”) in New Jersey.

This distinguishes silica litigation from other mass torts such as asbestos, talc, and opioids.

In re: Hair Relaxer Litigation




Federal (MDL 3060 -): *In re: Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation*, MDL No. 3060,
U.S. District Court for the Northern District of Illinois


The Hair Relaxer Litigation involves multiple conditions, including uterine cancer, ovarian cancer, uterine fibroids, and endometriosis.

This variety presents comparable challenges in establishing causation, as numerous potential exposures may have contributed to the development of a plaintiff's disease.

In re: Hair Relaxer Litigation



In re: Hair Relaxer Litigation




MDL Location: District Court of Northern Illinois

Data Considerations

Large Scale Torts – Data Sources



Data Sources



Depending upon the specific situation, there are a multitude of potentially relevant sources of information

Data Points for Large Scale Torts



Regardless of claim type, there are basic data elements that generally should be collected/considered

Biographical/Demographic

Name – DOB – DOD –
Location

Damages

Type (Physical, Mental,
Economic) – Impacts

Defense Costs

Invoice # – Invoice Date – Invoice
Amount – Claimant – Allocation

Case Information

Case # – File Date – Plaintiff
Firm

Settlement

Date – Amount – Terms

Injury

Disease – Manifestation Date – Diagnosis Date
– Treatment Date(s) – Product Use Date(s)

Sexual Abuse &
Molestation /
Trafficking

Medical
Devices

Pharmaceuticals

Environmental

Chemicals

Social
Media

Consumer
Products

Data Points - Pharmaceuticals



Example tort-specific fields to be considered in addition to the basic / commonly captured elements

Manufacturing and Sales Details

- Manufacturer Name
- Corporate History
- Location of Manufacturing
- Date of Manufacturing
- Lot Number
- Date of Sale
- Quantity

Product Details

- Product Type
- Dosage
- Proof of Purchase

(Pill, Liquid, Transdermal, Injectable, etc.)

Usage Details

- Start Date
- End Date
- Frequency
- Dosage

Data Points - Consumer Products



Example tort-specific fields to be considered in addition to the basic / commonly captured elements

(Consumable/Personal Product, Ingestible/Topical, etc.)

Manufacturing and Sales Details

- Manufacturer Name
- Corporate History
- Location of Manufacturing
- Date of Manufacturing
- Lot Number
- Date of Sale
- Quantity

Product Details

- Product Type
- Usage Instructions
- Proof of Purchase

Usage Details

- Start Date
- End Date
- Frequency/ Quantity

In re: PFAs Litigation




In re: Aqueous Film-Forming Products Liability Litigation, MDL No.: 2873, U.S. District Court for the District of South Carolina

A distinctive feature of the PFAs litigation is the breadth of diseases at issue, including kidney cancer, testicular cancer, liver cancer, thyroid disease, and ulcerative colitis.


This range complicates causation analysis, as identifying the source of a plaintiff's condition is difficult in the presence of multiple potential exposures.

MAP: PFAs Litigation



MDL: District Court of South Carolina

In re: PFAs Litigation




In re: GLP1/Ozempic Litigation




Federal (MDL 3163 - Vision Loss): *In re: GLP-1 Receptor Agonists Products Liability Litigation (NAION)*, MDL No. 3163, U.S. District Court for the Eastern District of Pennsylvania

New Jersey State Court (MCL): Case No. 638, *In re: GLP-1 Medications Gastrointestinal Injuries* (Multicounty Litigation).



The MDL is expected to become a major pharmaceutical mass tort over the next several years.


In re: GLP 1/ Ozempic Litigation



MDL: District Court of Eastern Pennsylvania

MCL: Bergen County, New Jersey


In re: GLP 1/ Ozempic Litigation



In re: Roundup Litigation




In re Roundup Litigation, Case No. 642, Master Docket No. BER-L-7019-25 (N.J. Super. Ct. Law Div. Bergen County).



Roundup - most commonly used pesticide in America with 280 million pounds of glyphosate are applied to nearly 300 million acres of U.S. farmland.

In re: Roundup Litigation




MDL: District Court of Northern California

State: Missouri


MCL: Bergen County, New Jersey

State court settlement efforts may be in jeopardy due to recent filings.

In re: Roundup Litigation



In re: Roundup Legislative Efforts



Passed – GA, ND, KY

Failed to Pass / Stalled- ID, WY, FL

Under Consideration – IA, MO, KS, OK, TN, NC, MS

In re: Depo-Provera Litigation



In re: Depo-Provera Products Liability Litigation, MDL No.:
3140, U.S. District Court for the Northern District of Florida


In December 2025, the FDA added a meningioma warning. Canada and the EU already had such warnings and that difference could likely be front and center as the litigation progresses.

In re: Depo-Provera Litigation



MDL: Northern District of Florida

In re: Depo-Provera Litigation



- The next milestones in the Depo-Provera litigation include rulings on pending Rule 702/Daubert motions challenging the admissibility of general causation experts, following completion of expert depositions and briefing pursuant to recent case management orders governing expert disclosure and motion practice.^[2]
- Daubert challenges scheduled for briefing are to conclude by May 29, 2026. The Court is also expected to rule on Pfizer's federal preemption arguments, which have been the subject of supplemental briefing and repeated discussion at MDL case management conferences, including whether failure to warn claims may proceed in light of the FDA's December 2025 approval of a meningioma warning for Depo-Provera.^[3]

Plaintiffs' Bar Role

The collage consists of several overlapping website components:

- Top Navigation:** A dark blue bar with a white logo on the left and a red button labeled "SCHEDULE A FREE CONSULTATION" on the right.
- Hero Section:** A blue background with the text "Depo-Provera Lawsuit" and a sub-headline "Recent studies have linked Pillar's controversial Depo-Provera to a higher risk of developing breast cancer."
- Case Study:** A white box with the title "Silicosis Lawsuit: Holding Employers and..." and a sub-headline "PFAS Water Contamination".
- Chat Window:** A dark blue chat window titled "Live Chat Online" showing a conversation with "Levin Papantonio". The transcript includes a disclaimer: "This transcript will be recorded by Levin Papantonio and its affiliates. By using this chat, you agree to our Terms of Use and Privacy Policy." and a "Switch to Text" button.
- Contact Form:** A white form titled "Free Case Evaluation" with fields for "FIRST NAME", "LAST NAME", "EMAIL ADDRESS", and "PHONE NUMBER". It also includes a "Subscribe" button and a "We've Got Your Back" section.
- Hero Section:** A red background with the text "CLICK TO YOUR FREE CONSULTATION" and a sub-headline "Our team is Chat with a real...".
- Footer:** A dark blue bar with a white logo on the left and a red button labeled "Click for Live Chat" on the right.
- Other Elements:** Various smaller text elements, including "PFAS Water Contamination", "Pesticide Lawsuits", and "We've Got Your Back".

Wrap Up:
Takeaways and Questions

YOUR PANEL



John Delascio, Esq.

Partner

Hinshaw & Culbertson LLP

E-Mail: jdelascio@hinshawlaw.com

Telephone: 312-704-3664



Leslie Lombardy, Esq.

Partner

O'Toole Scrivo, LLC

E-Mail: llombardy@oslaw.com

Telephone: 973-559-9834



Barry Trilla

Director for Quantitative Services

Alan Gray

E-Mail: btrilla@alangray.com

Telephone: 708-250-4113



Stacey White

AVP, Direct Claims

Resolute Management, Inc.

E-Mail: swhite@resolutemgmt.com

Telephone: (312) 345-2496



THANK YOU

Citations

- [1] Knauth, Dietrich. "Bayer's \$7.25 Billion Roundup Settlement Faces New Objections." *Reuters*, 22 May 2026, www.reuters.com/legal/government/bayers-725-billion-roundup-settlement-faces-court-objections-2026-05-22/.
- [2] Depo-Provera MDL Joint Update & Agenda | King Law
- [3] MDL 3140 Depo-Provera Lawsuit Updates | Jeffrey Glassman Injury Lawyers